Trump’s tariffs on pharmaceuticals intensify the challenges faced by India’s policymakers

Given that the United States represents nearly 40 percent of its exports, India’s pharmaceutical industry experienced a significant setback following the announcement of new tariffs

Context: The prospect of renewed protectionist measures by a potential future Trump administration, particularly the proposed 10% universal tariff on all imports into the US, poses a significant and multifaceted challenge for India’s pharmaceutical sector and its policymakers. This situation, highlighted by recent discussions, necessitates a proactive and comprehensive strategic response from India.

Introduction: India has long been recognized as the “pharmacy of the world,” a testament to its robust generic drug manufacturing capabilities, cost-effectiveness, and significant contribution to global health, particularly in developing nations. The US, being India’s largest export market for pharmaceuticals, represents a critical economic artery for this sector. Trump’s proposed tariffs, if implemented, threaten to disrupt this established trade dynamic, impacting everything from pricing and market access to the very structure of India’s pharmaceutical R&D and manufacturing.

Dimensions of the Challenge:

1. Economic Impact and Market Access:

• Direct Cost Increase: A 10% tariff would immediately increase the cost of Indian pharmaceutical exports to the US, eroding India’s competitive pricing advantage. This could lead to higher prices for US consumers or force Indian manufacturers to absorb the costs, impacting profitability.
• Market Share Erosion: Higher prices could make Indian generics less attractive compared to alternatives from other countries (potentially not subject to similar tariffs) or even domestic US production, leading to a loss of market share for Indian companies.
• Reduced Demand: Increased costs could translate to reduced demand from US buyers, impacting export volumes and overall revenue for Indian pharma companies.

2. Supply Chain Vulnerabilities and Diversification:

• Dependence on China for APIs: While India is a major finished drug manufacturer, it remains significantly dependent on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Tariffs on Indian finished products might expose this vulnerability further, as rising input costs combined with export tariffs could create a double whammy.
• Need for Reshoring/Diversification of API Production: The situation underscores the urgent need for India to accelerate its efforts under schemes like the Production Linked Incentive (PLI) to boost domestic API manufacturing and reduce reliance on single-source origins. This would build resilience into the supply chain.

3. Geopolitical and Trade Relations:

• India-US Bilateral Trade: Tariffs could strain the broader India-US trade relationship, potentially leading to retaliatory measures or complicating ongoing trade negotiations.
• WTO Implications: While the US might justify tariffs under domestic legislation, their consistency with WTO rules could be questioned, potentially leading to disputes.
• Global Trade Order: Trump’s protectionist stance challenges the multilateral trade order, and India, as a significant trading nation, needs to navigate this shift carefully, potentially seeking alliances with other affected countries.

4. Innovation and R&D Investment:

• Impact on Profitability: Reduced profitability due to tariffs could curtail the ability of Indian pharma companies to invest in crucial research and development (R&D), particularly in complex generics, biosimilars, and novel drugs.
• Shift in Focus: Companies might be forced to re-evaluate their R&D priorities, potentially shifting away from the US market or focusing on less R&D-intensive products.

5. Domestic Policy Response – A Multi-pronged Approach:

• Diplomatic Engagement: India must engage proactively with the US administration, emphasizing the mutual benefits of a robust pharmaceutical trade, the role of Indian generics in US healthcare cost containment, and the potential negative impact on American patients.
• Diversification of Export Markets: While the US is crucial, India needs to intensify efforts to diversify its export markets, focusing on regions like Europe, Africa, Latin America, and emerging economies.
• Strengthening Domestic Manufacturing: Doubling down on schemes like the PLI for APIs and KSMs is paramount to achieve self-reliance and reduce supply chain risks.

• Enhancing Competitiveness: Policymakers need to identify and remove domestic bottlenecks that increase manufacturing costs, streamline regulatory processes, and invest in infrastructure to boost the overall competitiveness of the Indian pharma sector.
• Promoting R&D: Incentivizing innovation in complex generics, biosimilars, and novel drugs, coupled with fostering a conducive R&D ecosystem, will be vital for long-term growth.
• Exploring Strategic Partnerships: Indian companies could explore joint ventures or strategic alliances with US counterparts to navigate tariff barriers or even consider establishing manufacturing bases in the US, albeit with careful cost-benefit analysis.
• Quality and Regulatory Excellence: Maintaining and enhancing India’s reputation for high-quality manufacturing and adhering to stringent global regulatory standards will be key to retaining trust and market access.

Conclusion:

Trump’s proposed tariffs present a formidable challenge, demanding a comprehensive and agile response from India’s policymakers. The situation is not merely an economic hurdle but a strategic inflection point for the Indian pharmaceutical industry. By prioritizing diplomatic engagement, strengthening domestic manufacturing and R&D, diversifying markets, and enhancing overall competitiveness, India can not only mitigate the adverse impacts of potential tariffs but also emerge as a more resilient and globally competitive pharmaceutical powerhouse. The time for strategic foresight and decisive action is now.

UPSC mains exam question based on the provided topic:

GS Paper II: Government policies and interventions for development in various sectors and issues arising out of their design and implementation. The effect of policies and politics of developed and developing countries on India’s interests and the Indian diaspora. Bilateral, regional, and global groupings and agreements involving India and/or affecting India’s interests.

Question 1. Discuss this statement in light of India’s long-term goals of self-reliance (Atmanirbhar Bharat) in pharmaceutical manufacturing. Evaluate the role of diplomatic engagement, diversification of export markets, and indigenous API production in safeguarding India’s strategic interests and global health commitments in such a protectionist trade environment. (250 words, 15 marks)

Question 2. Discuss the strategic implications of this vulnerability for India’s ‘pharmacy of the world’ status. How can India leverage policies like the Production Linked Incentive (PLI) scheme to enhance its self-reliance and resilience in the pharmaceutical supply chain? (150 words, 10 marks)

(Source – Indian Express)